Why is Vivanza Biosciences Ltd falling/rising?

Recent Price Movement and Market Context

Vivanza Biosciences has experienced a notable decline in its share price over the past few days, with a consecutive three-day fall resulting in a cumulative loss of 6.49%. Despite a modest positive return of 5.88% over the last month, the stock has underperformed the broader Sensex index over the year and longer periods. Specifically, the stock has delivered a negative return of 38.46% over the past year, contrasting sharply with the Sensex’s positive 8.40% gain. Over three and five years, the disparity widens further, with Vivanza Biosciences declining by 86.58% and 82.97% respectively, while the Sensex has appreciated by 39.89% and 69.39% in the same periods.

On the day in question, the stock underperformed its sector by 3.28%, reflecting a lack of buying interest relative to peers. This is compounded by a significant drop in delivery volume, which fell by 55.38% compared to the five-day average, signalling waning investor participation and possibly heightened caution among shareholders.

Fundamental Performance and Financial Health

While the company reported its highest quarterly net sales of ₹55.36 crores and achieved peak PBDIT and PBT less other income figures in September 2025, these positive results follow a period of flat performance in June 2025. Despite this recent uptick, the company’s long-term financial metrics remain weak. The average Return on Capital Employed (ROCE) stands at a modest 4.57%, indicating limited efficiency in generating returns from its capital base.

Moreover, operating profit growth has been negligible, with an annualised increase of just 0.59% over the past five years. This sluggish growth trajectory undermines investor confidence in the company’s ability to expand profitably. The firm’s debt servicing capacity is also a concern, with a high Debt to EBITDA ratio of 5.05 times, suggesting elevated leverage and potential financial strain.

Risk Factors and Market Sentiment

The stock is considered risky due to its negative EBITDA and trading at valuations that are unfavourable compared to its historical averages. Over the last year, profits have declined by 40%, exacerbating the negative sentiment. This financial deterioration is reflected in the stock’s poor returns and consistent underperformance relative to the BSE500 index over the past three years.

Investor caution is further evidenced by the majority shareholding being held by non-institutional investors, which may limit the stock’s liquidity and institutional support. The mixed signals from moving averages—where the price is above the 20-day and 100-day averages but below the 5-day, 50-day, and 200-day averages—indicate short-term weakness amid longer-term uncertainty.

Conclusion: Why the Stock is Falling

In summary, Vivanza Biosciences Ltd’s recent share price decline is primarily driven by its weak fundamental profile, including poor long-term profitability, high leverage, and negative earnings trends. Despite some positive quarterly results, the company’s inability to sustain growth and service debt effectively has weighed heavily on investor sentiment. The stock’s persistent underperformance against major benchmarks and falling investor participation further compound the downward pressure on its price.

Investors appear to be responding to these challenges by reducing exposure, as reflected in the declining delivery volumes and consecutive days of price falls. Until the company demonstrates stronger financial health and consistent profit growth, the stock is likely to remain under pressure in the market.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →